头孢他啶/阿维巴坦联合方案抗多重耐药铜绿假单胞菌的体内外研究
本研究通过体外棋盘滴定、时间杀菌试验、体外药效学模型及小鼠腹腔感染模型,评估头孢他啶/阿维巴坦(CZA)单用及联合多黏菌素B或氨曲南对多重耐药铜绿假单胞菌的疗效。结果显示CZA联合多黏菌素B在体外显著降低全部四株菌的菌落形成单位,并在小鼠中显著或呈趋势性降低死亡率和组织菌量;CZA联合氨曲南仅对产金属β-内酰胺酶(MBL)菌株在体内显示协同效应。
要点
- CZA联合多黏菌素B在体外对全部4株MDR-PA均显著降低菌落数。
- CZA联合多黏菌素B在小鼠中显著或趋势性降低死亡率和组织菌量。
- CZA联合氨曲南仅对MBL阳性菌株在体内显示协同作用。
核心结论
- CZA联合多黏菌素B可能是治疗MDR-PA的潜在有效选择。
- CZA联合氨曲南对MBL阳性铜绿假单胞菌在体内显示有希望的协同效应。
研究设计与样本
- 采用棋盘滴定、时间杀菌试验和体外药效学模型进行体外研究。
- 建立小鼠腹腔感染模型评估联合治疗体内疗效。
主要发现
- 体外药效学模型中,CZA联合多黏菌素B使全部4株菌的菌落形成单位显著减少。
- 体外药效学模型中,CZA联合氨曲南仅使3株菌的菌落减少。
- 小鼠模型中,CZA联合多黏菌素B组死亡率和组织菌量显著或呈趋势性下降。
- 小鼠模型中,CZA联合氨曲南仅降低MBL阳性菌感染小鼠的死亡率和组织菌量。
临床怎么用
- 对MDR-PA感染,可考虑CZA联合多黏菌素B方案。
- 对MBL阳性铜绿假单胞菌感染,CZA联合氨曲南可能具有协同作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ceftazidime/avibactam (CZA) is recognized as an efficacious treatment modality against multidrug-resistant Pseudomonas aeruginosa. Nevertheless, it encounters the challenge of escalating antimicrobial resistance. Employing combination regimens involving ceftazidime/avibactam may confer advantages. METHODS: Checkerboard titration, time-kill assays, and an in vitro pharmacodynamic model were employed to investigate the effectiveness of ceftazidime/avibactam alone and in combination in vitro. Additionally, an intraperitoneal infection mouse model was established to assess the efficacy of combination therapy in vivo. RESULTS: In the in vitro pharmacodynamic model, administration of ceftazidime/avibactam plus polymyxin B resulted in a significant reduction in colony-forming units of all four strains, whereas ceftazidime/avibactam plus aztreonam only reduced the colonies of three strains. Significant or trending declines in mortality and tissue colony counts of infected mice were observed in groups treated with ceftazidime/avibactam plus polymyxin B. Conversely, ceftazidime/avibactam combined with aztreonam only reduced mortality and tissue colonies in MBL-positive P.aeruginosa-infected mice. CONCLUSION: Combining ceftazidime/avibactam with polymyxin B might represent a potentially effective option against MDR-P.aeruginosa. Although the synergistic effect in vitro might not be readily apparent due to the potent bactericidal effect of aztreonam alone, the combination of ceftazidime/avibactam and aztreonam demonstrated promising synergistic effects on MBL-positive P.aeruginosa strains in vivo.
引用
- Zhuo J, Xu J, Chi Y, et al. Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies. J Antimicrob Chemother. 2026. PMID: 41549665. doi:10.1093/jac/dkaf495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。